Ligand Pharmaceuticals Incorporated (LGND) - Total Liabilities
Based on the latest financial reports, Ligand Pharmaceuticals Incorporated (LGND) has total liabilities worth $1.22 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore LGND strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Ligand Pharmaceuticals Incorporated - Total Liabilities Trend (1994–2025)
This chart illustrates how Ligand Pharmaceuticals Incorporated's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Ligand Pharmaceuticals Incorporated asset portfolio.
Ligand Pharmaceuticals Incorporated Competitors by Total Liabilities
The table below lists competitors of Ligand Pharmaceuticals Incorporated ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $154.41 Million |
|
Nice Ltd ADR
NASDAQ:NICE
|
USA | $1.31 Billion |
|
Matador Resources Company
NYSE:MTDR
|
USA | $7.24 Billion |
|
DigitalOcean Holdings Inc
NYSE:DOCN
|
USA | $1.87 Billion |
|
Astor Enerji AS
IS:ASTOR
|
Turkey | TL17.40 Billion |
|
CICT Mobile Communication Technology Co. Ltd. A
SHG:688387
|
China | CN¥6.81 Billion |
|
Hunan Gold Corp Ltd
SHE:002155
|
China | CN¥1.29 Billion |
|
Spring Airlines Co Ltd
SHG:601021
|
China | CN¥29.78 Billion |
Liability Composition Analysis (1994–2025)
This chart breaks down Ligand Pharmaceuticals Incorporated's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Ligand Pharmaceuticals Incorporated (LGND) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 30.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ligand Pharmaceuticals Incorporated's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ligand Pharmaceuticals Incorporated (1994–2025)
The table below shows the annual total liabilities of Ligand Pharmaceuticals Incorporated from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $543.42 Million | +388.10% |
| 2024-12-31 | $111.33 Million | +29.00% |
| 2023-12-31 | $86.30 Million | -47.75% |
| 2022-12-31 | $165.18 Million | -65.33% |
| 2021-12-31 | $476.43 Million | -27.01% |
| 2020-12-31 | $652.76 Million | -10.30% |
| 2019-12-31 | $727.68 Million | +3.97% |
| 2018-12-31 | $699.89 Million | +177.32% |
| 2017-12-31 | $252.37 Million | +9.38% |
| 2016-12-31 | $230.73 Million | +0.52% |
| 2015-12-31 | $229.54 Million | -1.75% |
| 2014-12-31 | $233.62 Million | +323.99% |
| 2013-12-31 | $55.10 Million | -29.15% |
| 2012-12-31 | $77.78 Million | -31.60% |
| 2011-12-31 | $113.70 Million | +37.74% |
| 2010-12-31 | $82.55 Million | -24.92% |
| 2009-12-31 | $109.95 Million | -39.52% |
| 2008-12-31 | $181.81 Million | +26.12% |
| 2007-12-31 | $144.16 Million | -51.74% |
| 2006-12-31 | $298.70 Million | -29.72% |
| 2005-12-31 | $425.04 Million | +4.23% |
| 2004-12-31 | $407.78 Million | +76.89% |
| 2003-12-31 | $230.53 Million | +17.26% |
| 2002-12-31 | $196.59 Million | +12.12% |
| 2001-12-31 | $175.35 Million | +4.04% |
| 2000-12-31 | $168.55 Million | +5.21% |
| 1999-12-31 | $160.20 Million | -4.30% |
| 1998-12-31 | $167.40 Million | +129.00% |
| 1997-12-31 | $73.10 Million | +8.14% |
| 1996-12-31 | $67.60 Million | +3.21% |
| 1995-12-31 | $65.50 Million | +221.08% |
| 1994-12-31 | $20.40 Million | -- |
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help figh… Read more